Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny’s sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *